Turna Ray

Based on encouraging data in mice, investigators are assessing if temozolomide-cisplatin can make patients' "cold" tumors respond to checkpoint blockade. 

Despite the registry's growth in content and utility, currently more than 80 percent of the clinical and genomic data comes from white patients, which AACR wants to change.

The NCI-funded project, which was delayed due to the pandemic, is poised to begin, and aims to provide actionable data and build a reference genome for American Indians.

Data presented at the AACR annual meeting suggests that some recurrent breast cancers after DCIS are actually new primary tumors in some high-risk patients.

A woman worried about her cancer risks gets tested through 23andMe upon the recommendation of a "holistic doctor" but isn't prepared for what the testing reveals.

The company is offering combined germline and somatic cancer testing, and sharing patients' variants identified through that testing in a new research registry.

A woman is sent for pancreatic cancer screening based on testing from a lab that refuses to share technical data and a doctor's misinterpretation of a VUS as pathogenic.

Precision oncology experts and molecular tumor boards are helping community oncologists decipher NGS reports, reduce reimbursement headaches, and improve patients' outcomes.

No physician had noticed that this endometrial cancer patient had a strong family history and physical signs of myotonic dystrophy, which is known to increase the risk of uterine cancers.

During its R&D day, 23andMe outlined the genetics rationale for two cancer drugs it is developing and said it will apply genotyping across trials to identify best responders.